A University College London study using UK primary care data found patients starting gabapentinoids — gabapentin or pregabalin — faced a higher risk of hospitalised drug poisoning, particularly in the first month of treatment and when the drugs were combined with benzodiazepines or opioids. Researchers analysed prescriptions in the Clinical Practice Research Datalink Aurum from 2010–2020, focusing on 16,827 people who experienced at least one drug poisoning hospitalization drawn from about 1.35 million people prescribed gabapentinoids. Compared with non-treatment periods, risk rose in the first four weeks (adjusted incidence rate ratio, aIRR 1.81). Co-prescription risk was notably higher: benzodiazepines with gabapentinoids had an aIRR of 3.95 (fourfold increase) and opioids with gabapentinoids an aIRR of 2.14 (doubling) for the first four weeks. The study also found drug-poisoning risk was elevated in the 90 days before gabapentinoid initiation (aIRR 2.09). The authors, noting the self-controlled case-series design cannot eliminate all time-varying confounding, urged clinicians to monitor patients closely at treatment initiation and avoid or minimise concurrent opioid or benzodiazepine prescribing.

President Donald Trump on April 16–17 nominated Dr. Erica Schwartz to lead the U.S. Centers for Disease Control and Prevention, naming three senior deputies alongside her: Sean Slovenski as deputy director and COO, Dr. Jennifer Shuford as deputy director and chief medical officer, and Dr. Sara Brenner as senior counselor for public health. Schwartz, a retired rear admiral in the U.S. Public Health Service Commissioned Corps and former deputy surgeon general in Trump’s first term, is a board‑certified preventive medicine physician with medical and public‑health credentials from Brown University and the Uniformed Services University and a law degree from the University of Maryland. The nomination must be approved by the Senate; NIH director Jay Bhattacharya is serving as acting CDC director during the likely months‑long confirmation process. The pick comes after a year of turmoil at the agency — including abrupt leadership changes, staffing and budget cuts, a shooting at CDC headquarters and controversy over vaccine policy under Health Secretary Robert F. Kennedy Jr. Many public‑health experts and CDC staff greeted the selection with guarded optimism, seeing Schwartz as a conventional, experienced choice but warning her authority could be constrained by political interference.

A team of about 50 researchers led by Paul Verweij at Radboud University Medical Center has warned of a "silent surge" in drug-resistant fungi in a Nature Medicine paper published April 2026. The researchers — from 16 organisations worldwide — say resistance is rising in pathogens including Candida auris, azole-resistant Aspergillus fumigatus and Trichophyton indotineae. They argue that resistance often originates in the environment, driven in part by widespread agricultural use of fungicides chemically related to medical azoles, and can spread long distances via airborne spores. People with weakened immunity, such as ICU patients, transplant recipients and cancer patients, face the greatest risk; Candida auris bloodstream infections can carry high mortality. The authors set out a five-step plan calling for increased awareness, strengthened surveillance, improved infection prevention and control, optimized antifungal use, and investments in diagnostics and new drugs. They urge the inclusion of antifungal resistance in the 2026 Global Action Plan on AMR and stress the need for coordinated One Health policies linking agriculture, environment and clinical practice.

A preprint analysis and Reuters report this week found that Eli Lilly’s tirzepatide, while producing larger average weight loss than Novo Nordisk’s semaglutide, was linked with greater losses of lean body mass. The Massachusetts data‑analytics firm nference analysed roughly 1,800 tirzepatide users and about 6,200 semaglutide users, finding tirzepatide associated with an average 1.1% greater lean mass loss at three months and about 2.0% more after 12 months. The preprint categorised a “depletive GLP‑1 metabotype” (>20% total weight loss and >5% lean mass loss) in 10.3% of tirzepatide patients versus 6.7% on semaglutide in the first year. Higher doses, longer treatment and baseline musculoskeletal pain correlated with greater lean mass decline for both drugs. Separately, U.S. prescription data for the week ending April 10 show Eli Lilly’s newly approved oral weight‑loss pill Foundayo had about 1,390 prescriptions versus more than 113,000 for Novo’s Wegovy pill in the same period. Market commentary and investor notes circulated April 16–17 highlighted potential competitive and access implications as the two companies press in the global GLP‑1 market.

Belgian biopharmaceutical group UCB said on April 17 it will acquire U.S.-based Neurona Therapeutics for $650 million upfront and up to $500 million in milestone payments, valuing the deal at as much as $1.15 billion. The acquisition, expected to close by the end of the second quarter of 2026, adds Neurona’s clinical-stage cell therapy NRTX-1001 — a pluripotent stem cell‑derived GABAergic interneuron therapy in Phase I/II trials for drug‑resistant mesial temporal lobe epilepsy — to UCB’s neurology portfolio. UCB said the transaction will not change its 2026 revenue guidance but expects adjusted EBITDA to grow in the high-single-digit to mid‑teens percentage range. Neurona’s backers include Fidelity and Schroders Capital; the startup previously raised significant private funding to advance its regenerative medicine programme. UCB described the move as a strategic expansion into advanced therapies aimed at durable, targeted repair of the nervous system for hard‑to‑treat seizure disorders.